Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (13501)	8/28/1998 10:09:00 AM
From: j g cordes	Respond to of 120523

News article received Friday, August 28, 1998 10:04:45 AM EST EMERGENCY MIGRATION PROGRAM HELPS MICROSOFT ACCESS USERS MOVE DATA TO SAFE Oracle(R) Databases Free Oracle8(TM) Migration Assistant, Oracle Lite Developers' Licenses Address Bug That Destroys Microsoft Database Records REDWOOD SHORES, Calif., Aug. 28 /PRNewswire/ -- Responding to customer fears about a newly discovered software bug that destroys information in Microsoft Access databases, Oracle Corp. (Nasdaq: ORCL) today announced an emergency migration program that helps developers and customers move their data and applications to proven, safe Oracle(R) databases. The program offers a secure, reliable solution for small and medium business users to migrate their applications to Oracle8(TM) workgroup databases. For developers, Oracle is offering a migration tool and Oracle Lite software to convert business applications for low-cost information management and broad mobile access via PCs and PalmPilots. As reported earlier this week by Internet newsgroups and C/NET's News.com, Microsoft Access users and developers recently learned that their Access databases could lose valuable data without warning. The Access bug causes edits made on one database record to be saved to another. For example, data associated with a specific customer or medical patient would be attached to the wrong account. According to C/NET's story August 25, "Developers fear that the bug could require reprogramming to applications already in use and that existing databases could be corrupted. Even worse, the problem could result in improper billing, diagnoses, or other potentially disastrous legal issues, according to developers." Microsoft officials have confirmed that the bug affects the last three versions of their database: Access 2.0, Access95 and Access97, the current version. "The short story is that Oracle offers a safe place to store valuable data records, and Microsoft clearly does not," said Mark Jarvis, senior vice president of Worldwide Marketing at Oracle. "Reliability is the top requirement for database users and developers. It's something Oracle takes for granted based on our 20-plus years of database experience. Unfortunately, Microsoft customers are learning they can't take reliability for granted." Oracle has posted a free Oracle Migration Assistant for Microsoft Access on its Web site. The migration tools quickly migrate Access data and applications to Oracle8, the industry's leading database across all operating systems including Windows NT and Unix. Developers can also receive developers' licenses for Oracle Lite, the world's most powerful lightweight database for mobile employees, Windows CE and PalmPilot users. For more information go to (URL) oracle.com or call 800-672-2531 extension 16800. More than 100 developers have posted concerns about the Microsoft Access bug to the comp.databases.ms-access Internet newsgroup since the bug was discovered by users last week. Developer Allen Browne posted step-by-step instructions at (URL) odyssey.apana.org.au, posing the question: "The fact that Access displays one record but writes changes to another destroys any claim it has to be a credible database. Can you afford to trust your data to it, if the wrong client gets your address, your donation, your invoice, your order, your merge letter?" For Microsoft SQL Server customers, Oracle also announced last week the beta releases of Oracle Migration Workbench, which will enable quick migration of entire SQL Server databases to Oracle8, and Oracle8 Wizards for Visual Studio, a suite of graphical tools that allow Windows NT developers to rapidly build Oracle8 applications by generating reusable code frameworks for Web, Visual Basic and C++ applications. Oracle Corporation is the world's leading supplier of software for information management, and the world's second largest software company. With annual revenues of $7.1 billion, the company offers its database, application server, tools and application products, along with related consulting, education and support services, in more than 140 countries around the world. For more information about Oracle, please call 650-506-7000. Oracle's World Wide Web address is (URL) oracle.com.

To: Jenna who wrote (13501)	9/3/1998 7:11:00 AM
From: Jenna	Read Replies (2) \| Respond to of 120523

GNE on Aug. 28 watch list.http://www.exchange2000.com/~wsapi/investor/reply-5610957 did finally get that FDA approval, stock started moving yesterday.FDA Advisory Panel Recommends Two Breast-Cancer Drugs By Robert Langreth, Staff Reporter of The Wall Street Journal BETHESDA, Md. -- Government advisers cleared the way for the approval of the firstdrug shown to reduce the risk of breast cancer in healthy women, though they cautioned the drug's benefits haven't been proved beyond a few years. In a landmark decision, a Food and Drug Administration scientific advisory panel overwhelmingly voted to recommend approval of Zeneca Group PLC's Nolvadex, generically called tamoxifen, for reducing the incidence of breast cancer in healthy women with anelevated risk of developing the disease. But, in a nuanced ruling, the committee stopped short of agreeing that the drug could actually prevent breast cancer over the long term,ruling that this hasn't yet been proved by clinical studies. Separately, in a second major decision, the FDA panel recommended the approval of a drug to treat breast cancer, Genentech Inc.'s Herceptin, believed to be one of the fewsignificant advances for treating advanced cases of the disease. Researchers are excited about the drug because it is the first of an expected wave of new therapies that directly attack cancer's genetic and biological causes.